IPO registrations (S-1, F-1) · Registrants

Prelude Therapeutics Inc

SEC CIK
1678660 · filings on EDGAR ↗
Former names
Prelude Therapeutics Inc. (2016–2017)
Registration
Form S-1, first filed 2020-09-04, last 2021-01-04; 2 initial registrations, 2 amendments
Outcome
Final prospectus filed 2020-09-25; declared effective 2020-09-24
Industry (SIC)
Pharmaceutical Preparations 2834
Incorporated in
DE
Business address
175 INNOVATION BOULEVARD, Wilmington, DE 19805
EIN
81-1384762
Ticker
PRLD (Nasdaq)
EDGAR entity type
operating
Insiders and CEO pay
Prelude Therapeutics Inc on the corporate pages

Offering terms

Proposed price range
$17.00–$19.00 per share (S-1/A filed 2020-09-21)
Final price
$19.00 per share, within the range (424B4 filed 2020-09-25, an initial public offering)
Shares sold
8,325,000
Gross proceeds
$158,175,000 before underwriting discounts and any over-allotment option
Listing
Nasdaq under the symbol PRLD
Lead underwriters
Morgan Stanley; Goldman Sachs (2,913,750 shares); BofA Securities (2,289,375 shares)

Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.

Filings 10

FiledFormWhat it isName as filedEDGAR
2020-09-04S-1S-1 (registration)Prelude Therapeutics Inc0001193125-20-240138 ↗
2020-09-16S-1/AS-1/A (amendment)Prelude Therapeutics Inc0001193125-20-246920 ↗
2020-09-21S-1/AS-1/A (amendment)Prelude Therapeutics Inc0001193125-20-249549 ↗
2020-09-24EFFECTEFFECT (declared effective)Prelude Therapeutics Inc9999999995-20-002573 ↗
2020-09-25424B4424B4 (final prospectus)Prelude Therapeutics Inc0001193125-20-254577 ↗
2021-01-04S-1S-1 (registration)Prelude Therapeutics Inc0001193125-21-000946 ↗
2021-01-06S-1MEFS-1MEF (added securities)Prelude Therapeutics Inc0001193125-21-003474 ↗
2021-01-06EFFECTEFFECT (declared effective)Prelude Therapeutics Inc9999999995-21-000059 ↗
2021-01-07424B4424B4 (final prospectus)Prelude Therapeutics Inc0001193125-21-004168 ↗
2021-11-24EFFECTEFFECT (declared effective)Prelude Therapeutics Inc9999999995-21-004484 ↗

Prospectus pages read 2

FiledFormRead asRangePriceSharesProceedsListingUnderwritersWhat was foundDocument
2020-09-21S-1/Aregistration statement$17.00–$19.008,325,000-Nasdaq PRLD3primary document; range, shares headline, cover names 3document ↗
2020-09-25424B4final prospectus$19.008,325,000$158,175,000Nasdaq PRLD3primary document; price sentence, shares headline, proceeds table, underwriting table 2, cover names 3document ↗

Officers, directors and large holders Forms 3, 4 and 5

InsiderRoleTitleFilingsYearsOn this site
667, L.P.Director,TenPercentOwner132020–2026
Baker Bros. Advisors (GP) LLCDirector,TenPercentOwner132020–2026
BAKER BROS. ADVISORS LPDirector,TenPercentOwner132020–2026
Baker Brothers Life Sciences LPDirector,TenPercentOwner132020–2026
BAKER FELIXDirector,TenPercentOwner132020–2026
BAKER JULIANDirector,TenPercentOwner132020–2026
Bonita David PDirector,TenPercentOwner112020–2026
Combs AndrewOfficerChief Chemistry Officer; EVP, Head of Chemistry122020–2026
Dier MardiDirector82020–2025
FRIEDMAN PAUL ADirector82020–2026
Mauro David JOfficerChief Medical Officer122020–2021
Morosini DeborahOfficerEVP, Chief of Clinical Affairs92020–2022
Neu KelvinDirector12020
ORBIMED ADVISORS LLCDirector,TenPercentOwner62020–2026
OrbiMed Capital GP VI LLCDirector,TenPercentOwner; TenPercentOwner62020–2026
Pierce ChristopherOfficerEVP and Chief of Business Oper72020–2021
Piper BrianOfficerChief Financial Officer42020–2021
Sandor VictorDirector112020–2026
Scherle PeggyOfficerChief Scientific Officer132020–2026
Vaddi KrishnaDirector,OfficerCEO; President, CEO192020–2026
ORBIMED CAPITAL LLCDirector,TenPercentOwner42020–2026
Babler MartinDirector72021–2026
Chardonnet LaurentOfficerChief Financial Officer112021–2024
Huang JaneOfficerPresident, CMO162022–2025
Lim Bryant DavidOfficerChief Legal Counsel, Corp Sec.; Chief Legal Officer, Corp Sec.; CLO, CFO, Corp Sec.; CLO, Interim CFO, Corp Sec.82023–2026
Scherer Paul CDirector12025
Dorton KatinaDirector32025–2026
Brusky Sean P.OfficerChief Business Officer12026
Morris Charles QOfficerChief Medical Officer22026
OrbiMed Genesis GP LLCDirector,TenPercentOwner12026
Kolchinsky PeterTenPercentOwner22026
RA Capital Healthcare Fund LPTenPercentOwner22026
RA CAPITAL MANAGEMENT, L.P.TenPercentOwner22026
Shah Rajeev M.TenPercentOwner22026

Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.

Private offerings before or after (Form D)

First filedIssuerIndustryOfferingSoldInvestorsFilings
2020-08-28Prelude Therapeutics IncBiotechnology$49,999,969$49,999,96971
2019-06-17Prelude Therapeutics IncBiotechnology$59,999,998$29,999,99961
2017-10-20Prelude Therapeutics IncBiotechnology$29,999,998$29,999,99872
2016-07-11Prelude Therapeutics Inc.Biotechnology$5,000,000$5,000,00081

Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.

Also on this site Fuzzy

RecordName as filedWhereDatasetMatched by
Business registrationPRELUDE THERAPEUTICS INCORPORATEDDEState business registriesname and state
Plan sponsorPRELUDE THERAPEUTICS, INCDEForm 5500 (employee benefit plans)EIN (EXACT)
Form D issuerPrelude Therapeutics IncDEForm D private offeringsCIK (EXACT)
SEC filerPrelude Therapeutics IncSEC filers (EDGAR)CIK (EXACT)
Trademark ownerPrelude Therapeutics IncorporatedDETrademarks (USPTO)name and state
Form 5500 plan sponsorPRELUDE THERAPEUTICS INCEIN (EXACT)

Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.

Others with the same interests

SIC industry Pharmaceutical Preparations, DE first:

More with this interest.

In other datasets, the same topic (Health) in DE:

Interests: Pharmaceutical Preparations · Health